Demand that used to go through telehealth compounders will likely shift toward gray market supply. - More buyer traffic to RUO sites - More FDA/DOJ attention on those sites, not less - Higher odds of seizures, payment-processor cuts, warning letters and occasional criminal cases if they sell at scale FDA has already been sending batches of warning letters to RUO peptide websites selling semaglutide, tirzepatide, and retatrutide under research labels. Things are about to get very interesting all around for GLP sellers and buyers alike.(CryptoDaddi)